Viewing Study NCT02764333


Ignite Creation Date: 2025-12-25 @ 2:54 AM
Ignite Modification Date: 2026-03-03 @ 12:42 AM
Study NCT ID: NCT02764333
Status: COMPLETED
Last Update Posted: 2021-11-30
First Post: 2016-05-04
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer
Sponsor: Memorial Sloan Kettering Cancer Center
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Ovarian Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None TPIV200/huFR-1 View
None Anti-PD-L1 View
None vaccine View
None 16-011 View